CD274 and gastric cancer: These findings are consistent with our earlier observations that CLDN18.2 positivity may attenuate the efficacy of PD-1/PD-L1 inhibitors, and further support the rationale for considering CLDN18.2-targeted CAR-T cell therapy as a promising treatment strategy for this subset of gastric cancer patients (22).